Hematologic Oncology Update cover image

Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series

Hematologic Oncology Update

00:00

Is CAR T More Effective Than Silticell?

You know, the way things are right now, I think people are happy just as they get a slot with any CAR T. But we do have two approved products. And I am curious how you indirectly would compare both efficacy and tolerability of those two. Both of them are pretty well tolerated. We've seen a little more neurotoxicity with one of them, delayed neurot toxicity with cell to cell.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app